HUP0004468A2 - Eletriptán-hemiszulfátot és koffeint tartalmazó gyógyszerkészítmény - Google Patents

Eletriptán-hemiszulfátot és koffeint tartalmazó gyógyszerkészítmény

Info

Publication number
HUP0004468A2
HUP0004468A2 HU0004468A HUP0004468A HUP0004468A2 HU P0004468 A2 HUP0004468 A2 HU P0004468A2 HU 0004468 A HU0004468 A HU 0004468A HU P0004468 A HUP0004468 A HU P0004468A HU P0004468 A2 HUP0004468 A2 HU P0004468A2
Authority
HU
Hungary
Prior art keywords
caffeine
pharmaceutical compositions
compositions containing
eletriptan hemisulphate
containing eletriptan
Prior art date
Application number
HU0004468A
Other languages
English (en)
Inventor
Anne Billotte
Valerie Denise Harding
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714081.8A external-priority patent/GB9714081D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP0004468A2 publication Critical patent/HUP0004468A2/hu
Publication of HUP0004468A3 publication Critical patent/HUP0004468A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Above=83;>(57) A találmány tárgya vizes gyógyszerkészítmény, amely 5-200mg/ml eletriptán-hemiszulfátot és 0,5-2 t/tf% koffeint tartalmaz. Atalálmány szerinti vizes gyógyszerkészítmények megnövekedettstabilitásúak. Ó
HU0004468A 1997-07-03 1998-07-01 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine HUP0004468A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9714081.8A GB9714081D0 (en) 1997-07-03 1997-07-03 Pharmaceutical compositions
GBGB9718270.3A GB9718270D0 (en) 1997-07-03 1997-08-28 Pharmaceutical compositions
PCT/EP1998/004176 WO1999001135A1 (en) 1997-07-03 1998-07-01 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Publications (2)

Publication Number Publication Date
HUP0004468A2 true HUP0004468A2 (hu) 2001-10-28
HUP0004468A3 HUP0004468A3 (en) 2004-07-28

Family

ID=26311826

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004468A HUP0004468A3 (en) 1997-07-03 1998-07-01 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Country Status (31)

Country Link
US (1) US6166025A (hu)
EP (1) EP0999841B1 (hu)
JP (1) JP3350061B2 (hu)
CN (1) CN1145486C (hu)
AT (1) ATE206921T1 (hu)
AU (1) AU724728B2 (hu)
BG (1) BG103930A (hu)
BR (1) BR9810658A (hu)
CA (1) CA2292673C (hu)
DE (1) DE69802097T2 (hu)
DK (1) DK0999841T3 (hu)
DZ (1) DZ2549A1 (hu)
EA (1) EA002174B1 (hu)
ES (1) ES2163291T3 (hu)
HK (1) HK1029282A1 (hu)
HR (1) HRP990416B1 (hu)
HU (1) HUP0004468A3 (hu)
ID (1) ID24528A (hu)
IL (1) IL133206A0 (hu)
IS (1) IS5283A (hu)
MA (1) MA26518A1 (hu)
NO (1) NO312993B1 (hu)
NZ (1) NZ501419A (hu)
OA (1) OA11227A (hu)
PL (1) PL337803A1 (hu)
PT (1) PT999841E (hu)
SI (1) SI0999841T1 (hu)
SK (1) SK284462B6 (hu)
TR (1) TR199903332T2 (hu)
UY (1) UY25078A1 (hu)
WO (1) WO1999001135A1 (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
WO2000064448A1 (en) 1999-04-27 2000-11-02 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
CO5190678A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia combinada para el tratamiento de la migrana
IL136961A0 (en) * 1999-06-30 2001-06-14 Pfizer Prod Inc 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
JP2008516998A (ja) * 2004-10-22 2008-05-22 ジン ショウ，コウ 可食用酸と／またはその酸性塩とコーヒーを含む薬剤組成物と無毒性コーヒー
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US20070111964A1 (en) 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
JP2012036167A (ja) * 2010-07-16 2012-02-23 Taisho Pharmaceutical Co Ltd 内服液剤
US8915245B2 (en) 2010-10-07 2014-12-23 Vapotherm, Inc. Nebulizer systems, apparatus and methods for respiratory therapy
JP5887894B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
JP5887893B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
EP2968204B1 (en) * 2013-03-15 2019-05-15 Robert I. Henkin Phosphodiesterase inhibitors for treating taste and smell disorders
JP2016527059A (ja) 2013-08-08 2016-09-08 ベイポサーム， インコーポレイティド 呼吸器治療凝縮アダプタ
NL1040474C2 (en) 2013-10-31 2015-05-04 Veramed B V Nasal compositions stimulating ciliary activity.
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
FR3053334B1 (fr) * 2016-06-30 2018-07-27 L'oreal Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et de compose de xanthine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
OA11227A (en) 2003-07-18
HRP990416B1 (en) 2002-04-30
UY25078A1 (es) 2000-12-29
JP3350061B2 (ja) 2002-11-25
CA2292673A1 (en) 1999-01-14
EA199901100A1 (ru) 2000-08-28
BG103930A (en) 2000-07-31
JP2000516262A (ja) 2000-12-05
DE69802097D1 (de) 2001-11-22
PL337803A1 (en) 2000-09-11
HRP990416A2 (en) 2000-04-30
SI0999841T1 (hu) 2001-12-31
BR9810658A (pt) 2000-10-03
US6166025A (en) 2000-12-26
DZ2549A1 (fr) 2003-02-08
NZ501419A (en) 2000-09-29
CN1145486C (zh) 2004-04-14
CN1261279A (zh) 2000-07-26
AU724728B2 (en) 2000-09-28
WO1999001135A1 (en) 1999-01-14
NO312993B1 (no) 2002-07-29
PT999841E (pt) 2002-02-28
DE69802097T2 (de) 2002-03-14
MA26518A1 (fr) 2004-12-20
NO995887D0 (no) 1999-12-01
EP0999841B1 (en) 2001-10-17
ID24528A (id) 2000-07-20
EA002174B1 (ru) 2002-02-28
CA2292673C (en) 2003-04-22
IL133206A0 (en) 2001-03-19
ATE206921T1 (de) 2001-11-15
HUP0004468A3 (en) 2004-07-28
NO995887L (no) 2000-03-02
SK284462B6 (sk) 2005-04-01
SK182899A3 (en) 2000-09-12
DK0999841T3 (da) 2001-11-19
TR199903332T2 (xx) 2000-09-21
EP0999841A1 (en) 2000-05-17
AU8856998A (en) 1999-01-25
ES2163291T3 (es) 2002-01-16
HK1029282A1 (en) 2001-03-30
IS5283A (is) 1999-11-30

Similar Documents

Publication Publication Date Title
HUP0004468A2 (hu) Eletriptán-hemiszulfátot és koffeint tartalmazó gyógyszerkészítmény
AU2420897A (en) Meta-substituted phenylene sulphonamide derivatives
AU629669B2 (en) Diarylacetylenes, the preparations and use thereof
HUP0104573A2 (hu) Agrokémiai készítmények
TW239126B (hu)
HUP9802221A2 (hu) Parazitaellenes hatású markfortin- és paraherkvamidszármazékok
HUP0004926A3 (en) 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring, pharmaceutical compositions containing them and their use
GR3033661T3 (en) Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
NO954072D0 (no) Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler
WO2000039083A3 (en) Pyrazole compounds and uses thereof
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
AU580079B2 (en) Acetylenic phenoxypropanol derivatives and pharmaceutical compositions for the treatment of hypertension
HU9403653D0 (en) New pharmaceutical use of 1,2,3,4,4a,5,10,10a-octahydro-benzo(g) quinoline derivatives
TW371661B (en) Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
HUP0302255A2 (hu) Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO923266D0 (no) Heksahydrobenzo(f)quinolinoner
TR200002293T2 (tr) Farmasötik bileşimler.
AU580890B2 (en) P-acylaminobenzamides
AU4956193A (en) Stable, highly concentrated formulations of fluorescein derivatives
HUP9900863A3 (en) 4,4-(disubstituted)cyclohexan-1-ol derivatives pharmaceutical compositions containing these compounds and use thereof

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees